Radiation Oncology

Lizza Hendriks, MD, PhD, discussed why every patient with CNS metastases deserves a multidisciplinary team discussion.

Ayal Aizer, MD, MHS, discusses radiation necrosis as the next major challenge in stereotactic radiosurgery for brain metastases and how clinicians can address it.

Ayal Aizer, MD, MHS, explains how expanded trial data have broadened eligibility for stereotactic radiosurgery in patients with brain metastases, including higher tumor counts.

Lizza Hendriks, MD, PhD, discussed why excluding patients with brain metastases from clinical trials is no longer ethical.

The next major problem to tackle for SRS in brain metastases management is how to handle necrosis rates, according to Ayal Aizer, MD, MHS.

Laura Alder, MD, discussed a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases excluded from DeLLphi-304.

Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.

Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.

A new ASTRO clinical practice guideline expands radiotherapy recommendations across resectable, locally advanced, recurrent, and metastatic pancreatic cancer.

A post-hoc analysis of the ARISTOTLE trial demonstrated that patients with rectal cancer with high tumor cell density had improved DFS and OS.

A multidisciplinary panel broke down ILC's distinct biology, imaging challenges, and emerging trial data, including OFSET and SUMMIT.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

In a real-world CASCADE database analysis, prophylactic cranial irradiation was associated with a median overall survival of 29.8 months in limited-stage SCLC.

Data from the PSMAddition trial support the approval of the radioligand-based regimen for this prostate cancer population.

Based on phase 2 data, adding consolidative thoracic radiation cannot be recommended outside of clinical trials for unselected patients with ES-SCLC.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.

The latest conversation in RadOnc on the Run explores patient and provider considerations for navigating cancer diagnosis, treatment, and recovery.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Efficacy with carboplatin-based induction-concurrent chemotherapy was noninferior to cisplatin, representing a viable alternative for patients with LA-NPC.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.

Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.